Intellia's Data Has Underlined Huge Potential Of Gene Therapeutics And There Will Be More Soon

Summary :

Intellia is a gene therapy specialist pioneering CRISPR-Cas9 technology.

Its recently released data in ATTR Amyloidosis stunned analysts, showing mean reduction in TTR Serum levels of up to 96%.

This was the first ever clinical proof of the safety and efficacy of an in-vivo CRISPR genome editing technology in a human trial, and sent Intellia's share price up by >100%.

Intellia will release more data from the trial and initiate a single-dose expansion cohort before the end of the year.

SOURCE : Edmund Ingham, Aug. 31, 2021, Seeking Alpha
https://seekingalpha.com/article/4452837...